Literature DB >> 22990616

One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation.

Yukari Shirakata1, Chieko Shiragami, Ayana Yamashita, Eri Nitta, Atsushi Fujiwara, Fumio Shiraga.   

Abstract

PURPOSE: Our aim was to study the efficacy of combined triple therapy with intravitreal bevacizumab injections (IVB), posterior sub-Tenon injection of triamcinolone acetonide (STTA), and reduced laser fluence photodynamic therapy (RFPDT) in Japanese patients with retinal angiomatous proliferation (RAP).
DESIGN: This was a retrospective, observational, consecutive case series.
METHODS: Fifteen consecutive RAP treatment-naïve eyes were treated with triple therapy of IVB, STTA, and RFPDT (25 J/cm(2) of laser fluence). Whenever there was a recurrence of retinal-retinal anastomosis (RRA) or retinal-choroidal anastomosis (RCA) and marked leakage from subretinal neovascularization, the triple therapy was reapplied. When there were only intraretinal exudative and/or hemorrhagic changes without distinct RRA or RCA, IVB alone was applied.
RESULTS: The mean logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA) at baseline improved significantly (from 0.489 to 0.294 12 months) (paired t test, p = 0.043). LogMAR BCVA at 12 months was stable or improved by ≥ 0.2 in 14 eyes (93.3 %). Mean number of triple therapy instituted during the 12-month study period was 1.2, and mean number of IVB treatments was 1.4.
CONCLUSION: Combined IVB, STTA, and RFPDT for RAP was effective in maintaining or improving VA at 1 year. In addition, the number of treatments could be markedly reduced.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22990616     DOI: 10.1007/s10384-012-0183-y

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  46 in total

1.  Combination therapy of ranibizumab and photodynamic therapy for retinal angiomatous proliferation with serous pigment epithelial detachment in Korean patients: twelve-month results.

Authors:  Mee Yon Lee; Kyu Seop Kim; Won Ki Lee
Journal:  Retina       Date:  2011-01       Impact factor: 4.256

2.  Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone.

Authors:  Ilse Krebs; Katharina Krepler; Ulrike Stolba; Alexandra Goll; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-03       Impact factor: 3.117

3.  Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Authors:  Ryan M Rich; Philip J Rosenfeld; Carmen A Puliafito; Sander R Dubovy; Janet L Davis; Harry W Flynn; Serafin Gonzalez; William J Feuer; Richard C Lin; Geeta A Lalwani; Jackie K Nguyen; Gaurav Kumar
Journal:  Retina       Date:  2006 May-Jun       Impact factor: 4.256

4.  Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation.

Authors:  Sandra Joeres; Florian M A Heussen; Tobias Treziak; Silvia Bopp; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-04-17       Impact factor: 3.117

5.  Photodynamic effects on choroidal neovascularization and physiological choroid.

Authors:  Ursula Schmidt-Erfurth; Stephan Michels; Irene Barbazetto; Horst Laqua
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-03       Impact factor: 4.799

6.  Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.

Authors:  Mandeep S Dhalla; Gaurav K Shah; Kevin J Blinder; Edwin H Ryan; Robert A Mittra; Asheesh Tewari
Journal:  Retina       Date:  2006 Nov-Dec       Impact factor: 4.256

7.  Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration.

Authors:  J S Slakter; L A Yannuzzi; U Schneider; J A Sorenson; A Ciardella; D R Guyer; R F Spaide; K B Freund; D A Orlock
Journal:  Ophthalmology       Date:  2000-04       Impact factor: 12.079

8.  Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells.

Authors:  Philip L Penfold; Li Wen; Michele C Madigan; Nicholas J C King; Jan M Provis
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-09       Impact factor: 4.799

9.  Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).

Authors:  Lazaros Konstantinidis; Evangelia Mameletzi; Irmela Mantel; Jean-Antoine Pournaras; Leonidas Zografos; Aude Ambresin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-04-29       Impact factor: 3.117

10.  Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes.

Authors:  Ursula Schlötzer-Schrehardt; Arne Viestenz; Gottfried O H Naumann; Horst Laqua; S Michels; Ursula Schmidt-Erfurth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-08-27       Impact factor: 3.117

View more
  3 in total

1.  Photodynamic therapy combined with intravitreal bevacizumab and sub-tenon triamcinolone acetonide injections for age-related macular degeneration.

Authors:  Chikako Yoshizawa; Wataru Saito; Shigeki Hirose; Hirokuni Kitamei; Kousuke Noda; Susumu Ishida
Journal:  Jpn J Ophthalmol       Date:  2012-10-24       Impact factor: 2.447

2.  Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano
Journal:  Jpn J Ophthalmol       Date:  2012-12-04       Impact factor: 2.447

Review 3.  Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration.

Authors:  Paris Tranos; Athanasios Vacalis; Solon Asteriadis; Stavrenia Koukoula; Athanasios Vachtsevanos; Georgia Perganta; Ilias Georgalas
Journal:  Drug Des Devel Ther       Date:  2013-06-17       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.